How should long-acting beta2-agonists be used in asthma management?

How should long-acting beta2-agonists be used in asthma management?

• A. Should be used as monotherapy alone.
• B. Should be avoided entirely.
• C. Should only be used for asthma prophylaxis and usually combined with an inhaled corticosteroid or leukotriene.
• D. Should be used for immediate relief during an attack.

Answer: (C)

Long-acting beta2-agonists are maintenance medicines used to prevent asthma symptoms by keeping the airways consistently open over time. They’re not for immediate relief and they don’t treat the underlying inflammation by themselves, which is why they’re not used as monotherapy. The safest and most effective approach is to use them regularly as part of a controller strategy, usually in combination with an inhaled corticosteroid to address the inflammatory nature of asthma. This ICS-LABA combination reduces the risk of severe flares and improves overall control. In some regimens, a leukotriene modifier may also be used alongside, but the key idea is that LABAs are added to anti-inflammatory therapy, not used alone. For quick relief during an attack, a short-acting inhaler is the appropriate choice.

Long-acting beta2-agonists are maintenance medicines used to prevent asthma symptoms by keeping the airways consistently open over time. They’re not for immediate relief and they don’t treat the underlying inflammation by themselves, which is why they’re not used as monotherapy. The safest and most effective approach is to use them regularly as part of a controller strategy, usually in combination with an inhaled corticosteroid to address the inflammatory nature of asthma. This ICS-LABA combination reduces the risk of severe flares and improves overall control. In some regimens, a leukotriene modifier may also be used alongside, but the key idea is that LABAs are added to anti-inflammatory therapy, not used alone. For quick relief during an attack, a short-acting inhaler is the appropriate choice.